IMVT
Immunovant IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.49B
P/E Ratio
—
EPS
$-2.67
Beta
0.67
52W High
$30.09
52W Low
$13.36
50-Day MA
$26.10
200-Day MA
$22.08
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-486.75M |
| Operating Margin | 0.00% |
| Return on Equity | -69.40% |
| Return on Assets | -41.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.85 |
| Price-to-Book | 5.91 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $203.53M |
| Float | $77.20M |
| % Insiders | 57.26% |
| % Institutions | 54.29% |
Historical Volatility
HV 10-Day
56.08%
HV 20-Day
51.78%
HV 30-Day
56.94%
HV 60-Day
51.42%
HV Rank
77.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($40.29 target)
2
Strong Buy11
Buy5
HoldData last updated: 4/29/2026